Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glioblastoma mutliforme

- PMLiVE

Breath test could predict response to immunotherapy

Study found device accurately predicted responses in lung cancer

- PMLiVE

Third strike for BMS’ Opdivo in brain cancer

Despite failing first endpoint, trial is set to continue

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

Celgene building

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Currently in the middle of merger

Bristol Myers Squibb logo

Opdivo trial overshadows BMS financial results

Hope remains in Celgene merger

- PMLiVE

Liver cancer failure dents Opdivo potential by $1bn, says analyst

Adds to bad news of forced Otezla sell-off

- PMLiVE

Bad news for BMS as Keytruda kidney cancer combo approved

Opdivo and Yervoy combination will be squeezed

- PMLiVE

Keytruda combo outshines Opdivo in kidney cancer

BMS also on the backfoot after Nektar data release

Bristol Myers Squibb logo

BMS isn’t phased by Opdivo’s slowing growth – for now

Lung cancer filing withdrawn after FDA reservations

- PMLiVE

EU approval for Opdivo combo in renal cell cancer

BMS one step ahead of rivals

- PMLiVE

BMS to test Vedanta’s bacterial therapy with Opdivo

Will be trialled in those with advanced or metastatic cancers

- PMLiVE

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

But it is only available via the CDF for now

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links